摘要
目的评价对于中国患者脑血管病后降压治疗是否可以预防脑卒中再发。方法采取双盲、安慰剂对照的试验方法,将患者随机分入对照组(n=2825)和干预组(吲达帕胺2.5 mg/d,n=2840)。一级终点事件为致死或非致死性再发脑卒中,二级终点事件为主要的致死或非致死心血管病事件。结果平均收缩压和舒张压分别为153.8和92.8 mm Hg。在随访中期(第2年),干预组收缩压/舒张压较对照组平均下降了6.8/3.3 mm Hg。干预组总共有159例再发脑卒中,对照组为219例(干预组HR=0.70;95%CI0.57～0.86;P<0.01)。干预组有199例发生心血管病事件,对照组为258例(HR=0.74;95%CI0.62～0.89;P=0.002)。结论吲达帕胺降压治疗可以降低中国人脑血管病患者再发脑卒中和心血管病事件。
Objective To determine whether blood pressure（BP） reduction prevents secondary stroke in Chinese patients with prior cerebrovascular diseases in China.Methods Patients,in a double-blind,placebo-controlled trial,were randomized into two groups： 2825 patients received a placebo and 2840 patients received 2.5 mg of indapamide daily.The primary outcomes was the recurrence of fatal or nonfatal strokes and secondary outcomes was major fatal and nonfatal cardiovascular events,respectively.Results The average systolic/diastolic BP at randomization was 153.8/92.8 mm Hg.At a median of 2 years follow-up,BP was,6.8/3.3 mm Hg lower on average in patients on active treatment than that on placebo group.159 patients on indapamide and 219 patients on placebo had recurrent strokes（hazard ratio for indapamide was 0.70;95% CI 0.57 to 0.86;P〈0.01）.In addition,199 patients on indapamide and 258 patients on placebo had cardiovascular events（hazard ratio was 0.74;95% CI 0.62 to 0.89;P=0.002）.Conclusions BP lowering by indapamide treatment reduced the recurrence of stroke and the incidence of cardiovascular events in Chinese patients with prior cerebrovascular disease.
出处
《中华高血压杂志》
CAS
CSCD
北大核心
2010年第4期329-334,共6页
Chinese Journal of Hypertension
关键词
降压治疗
血压
脑卒中
二级预防
Antihypertensive treatment
Blood pressure
Stroke
Secondary prevention
